SCHEMBL7944667

SCHEMBL7944667

Nc1ncccc1NCc1cccc(NC(=O)c2ccc(Br)cn2)c1

nearest known ligand 0.70

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 17/20 0.70
PARP1 P09874 1/20 0.47
APP P05067 3/20 0.46
AURKA O14965 1/20 0.45
RPS6KB1 P23443 1/20 0.45
AURKB Q96GD4 1/20 0.45
CTSD P07339 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7942883 0.89 BACE1 (0.63) BACE1PARP1AURKARPS6KB1AURKB
SCHEMBL7933183 0.89 BACE1 (0.71) BACE1AURKARPS6KB1AURKB
SCHEMBL7944661 0.89 BACE1 (0.71) BACE1AURKARPS6KB1AURKB
SCHEMBL7933424 0.88 BACE1 (0.73) BACE1AURKARPS6KB1AURKB
SCHEMBL7940965 0.88 BACE1 (0.70) BACE1AURKARPS6KB1AURKB
SCHEMBL7940722 0.86 BACE1 (0.76) BACE1AURKARPS6KB1AURKB
SCHEMBL12301753 0.86 BACE1 (0.76) BACE1PARP1AURKARPS6KB1AURKB
SCHEMBL7941381 0.86 BACE1 (0.52) BACE1APPCTSD
SCHEMBL7942385 0.85 BACE1 (0.67) BACE1AURKAAURKB
SCHEMBL7942377 0.85 BACE1 (0.67) BACE1AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885PARP1 970/4885APP 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.